| Literature DB >> 991075 |
S S Legha, M Slavik, S K Carter.
Abstract
Nafoxidine is a nonsteroidal antiestrogen available as an investigational agent from the Investigational Drug Branch of the National Cancer Institute. It has been used effectively in the treatment of breast cancer patients. A cumulative response rate of 31% is reported for a total of 200 patients treated with this drug. Most patients have been treated with a dose of 60 mg three times a day. Side effects include dryness of skin, photosensitivity reactions and, less commonly, partial hair loss. There is a strong correlation of response to nafoxidine with the presence of estrogen receptor in the tumor and also with the response to previous hormonal treatment. Nafoxidine is a useful addition to the list of hormonal treatments in the therapy of breast cancer.Entities:
Mesh:
Substances:
Year: 1976 PMID: 991075 DOI: 10.1002/1097-0142(197610)38:4<1535::aid-cncr2820380415>3.0.co;2-m
Source DB: PubMed Journal: Cancer ISSN: 0008-543X Impact factor: 6.860